Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
GLORY-OSA is a multicenter, randomized, open-label Phase 3 clinical study (NCT06931028) comparing the efficacy and safety of mazdutide 9mg versus placebo in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity (BMI ≥ 28 kg/m2).The primary endpoint is the change in apnea-hypopnea index (AHI) from baseline to Week 48.
Globally, an estimated 425 million people aged 30 to 69 live with moderate-to-severe OSA, with China bearing the highest burden at approximately 66 million cases[1]. However, the diagnosis rates remain critically low, with less than 1% in China and only 20% in the U.S.[2],[3] The condition disproportionately affects individuals living with obesity, with a prevalence of 40%, increasing to 80.5% among those undergoing bariatric surgery[4],[5]. OSA-associated co-morbidities, including hypertension, cardiac arrhythmias, stroke, and metabolic syndrome, are strongly correlated with OSA severity[6],[7].
Positive airway pressure (PAP) is the first-line treatment for OSA, and certain patients experience transformative benefits from PAP. Challenges exist, however, as many others are unable to accept or adhere to PAP treatment due to the burdensome nature of the therapy. Moreover, current evidence does not strongly support a direct link between PAP and improved cardiometabolic outcomes (e.g., mortality, hypertension, myocardial infarction, stroke)[8]. Recently, the FDA approved Zepbound® (tirzepatide), a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist, as the first and only prescription medicine for moderate-to-severe OSA in adults with obesity[9]. There is currently no approved treatment for OSA in China[1], highlighting a significant unmet medical need. The literature suggests[10],[11],[12] that a 10% reduction in weight is associated with a 26% decrease in AHI, and that each 1-unit reduction in BMI corresponds to a 2-3 unit decrease in AHI. As such, weight loss medications have emerged as potential treatments for OSA.
Professor Tianpei Hong, the Principal Investigator of the Study, Peking University Third Hospital, stated, 'Patients with untreated OSA face significantly increased risks of cardiovascular diseases, metabolic disorders, neurocognitive decline, and traffic accidents. Their quality of life and labor capacity are often severely hampered. The OSA proportion of patients living with obesity is large and grows year after year. Despite this, an effective drug treatment regimen for OSA is lacking in China[13]. In our Phase 3 study GLORY-1[14], mazdutide showed good weight loss efficacy with multi-cardiovascular metabolism improvement, and a well-tolerated safety profile, which positions mazdutide as the world's first dual GCG/GLP-1 receptor targeted drug for patients with OSA and obesity. I will work closely with the GLORY-OSA research team to ensure the successful and high-quality completion of this study, with the ultimate goal of obtaining robust clinical evidence and expanding treatment options for Chinese patients with moderate-to-severe OSA and obesity.'
Dr. Lei Qian, Senior Vice President of Clinical Development at Innovent, stated, 'We have developed different doses and regimens of mazdutide to address the diverse treatment needs of patients with different indications. The development of mazdutide for OSA specifically targets the treatment needs of Chinese patients with moderate-to-severe OSA and obesity (BMI ≥ 28 kg/m2). In a Phase 2 study, mazdutide 9 mg achieved an 18.6 % weight loss compared to placebo, along with notable cardiovascular and metabolic benefits. The 9 mg regimen also features a simple titration schedule and a favorable safety profile. We are optimistic that the GLORY-OSA study will further validate mazdutide's powerful efficacy and good safety, and provide a promising pharmacologic alternative to PAP, the current standard of care for patients with moderate-to-severe OSA.'
About Mazdutide (IBI362)
Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity.
Currently, Mazdutide has two NDAs accepted for review by NMPA, including for:
Mazdutide is currently being evaluated in seven Phase 3 clinical studies, including:
Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and the other four studies are currently ongoing.
In addition, several new clinical studies of mazdutide are initiated or planned, including:
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.
Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Forward-looking statement
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', 'intend' and similar expressions, as they relate to Innovent Biologics ('Innovent'), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
View original content: https://www.prnewswire.com/news-releases/innovent-announces-completion-of-first-participant-dosed-in-the-seventh-phase-3-clinical-trial-glory-osa-of-mazdutide-in-china-302481798.html
SOURCE Innovent Biologics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
Phil Knight, Ex-Nike Chief, and His Wife Pledge $2 Billion to Oregon Cancer Center
Phil Knight, a co-founder of Nike, and his wife, Penny Knight, will give $2 billion to the cancer research center at Oregon Health & Science University, a gift the institution billed as the largest single donation to a university in the United States. The university said that the donation would help it expand and accelerate diagnostic capabilities, ensure access to innovative clinical trials and simplify the experience for patients and families. Its main campus is in Portland, Ore. In 2008, the university named its cancer institute after the Knights after receiving a $100 million gift from them. And in 2013, the couple, who live in Oregon, pledged an additional $500 million to the university if it could match the sum in two years as part of a cancer challenge, which it did. 'We couldn't be more excited about the transformational potential of this work for humanity,' the couple said in a statement provided by the university. Mr. Knight, 87, who is synonymous with the Nike swoosh logo, stepped down as president and chief executive of the Oregon-based sneaker and athletic wear giant in 2004. In 2016, he retired as the company's chairman. Dr. Brian Druker, the cancer institute's chairman of leukemia research, said in a statement on Thursday that the couple's previous donations had helped establish a large-scale early cancer detection program. The cancer challenge also spurred the development of numerous blood tests to detect cancer in its early stages and empowered the center to lead the way in targeted therapies and precision medicine, he said. 'Penny and Phil Knight have always challenged us to do what no one else is doing,' Dr. Druker said. 'It can seem impossible to navigate the health care system after being diagnosed with cancer. We're going to change that. We have revolutionized the way we detect and treat cancer.' Worth an estimated $35.4 billion, according to Forbes, Mr. Knight is widely known for his philanthropy, especially to his alma maters. At the University of Oregon, where he ran track, he is the most famous booster, and several buildings carry his family's name. There is the Knight Library, and the university's basketball arena is named after Phil and Penny Knight's son, Matthew, who died in a scuba diving accident in 2004. In 2016, Mr. Knight pledged $400 million to Stanford University, where he graduated from business school, to recruit graduate students from around the globe to address society's most intractable problems, including poverty and climate change. Ten-figure donations to U.S. higher learning and medical research institutions are not uncharted. In 2018, Michael R. Bloomberg, the billionaire businessman and former mayor of New York City, pledged $1.8 billion to his alma mater, Johns Hopkins University, to create a fund that would help low- and moderate-income students attend without having to worry about the cost. And in 2024, the 93-year-old widow of a Wall Street financier donated $1 billion to a Bronx medical school, the Albert Einstein College of Medicine, with instructions that the gift be used to cover tuition for all students going forward.
Yahoo
2 hours ago
- Yahoo
Vicarious Surgical delays robot timeline
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Vicarious Surgical CEO Stephen From, who started his job last week, said Tuesday the company no longer expects to begin a clinical trial for its surgical robot by the end of this year and will instead focus on completing the design for the commercial version of the system. The company's shares slid more than 24% to end at $7.83 on Wednesday, according to Yahoo Finance. The clinical trial's timing will determine when the robot developer submits its de novo filing to the Food and Drug Administration, From said on Vicarious' second-quarter earnings call. Vicarious had planned to make its FDA submission in late 2026, after delaying the start of the trial. The company plans to conduct an assessment over about four to six weeks to gauge readiness for verification of the system, From said, adding he would work with Vicarious' board and investor base to evaluate the capital strategy for supporting its goals. Dive Insight: Vicarious, which counts large for-profit hospital operator HCA Healthcare and Bill Gates among its investors, is developing a single-port robotic system for abdominal procedures that will vie for market share with robot industry leader Intuitive Surgical. Vicarious is initially targeting hernia, gallbladder, gastrointestinal and gynecology procedures. From, who joined Vicarious as co-founder Adam Sachs moved into the role of president, said the single-port robotic market is still in its early stages, and he believes the company's differentiated platform and strong technical foundation will advance minimally invasive surgery. 'I see an industry here, which is dominated by one player, and I see a lot of others that are trying to copy what they're doing, and I saw this team wasn't,' said From. 'This is a project and this is a system and a company that is worth investing in for the long term, because this is a system that isn't just a copycat. This is a system that deserves market share.' Vicarious ended the second quarter with about $24 million in cash and expects its cash burn to be about $50 million for fiscal 2025. The company will likely need to seek non-dilutive financing to maintain operations or meaningfully cut expenses, BTIG analyst Ryan Zimmerman said in a note to clients Tuesday. 'It's clear that the company is undergoing a pause until further notice and [management] does not have a clear answer as to how this may impact longer-term timelines,' Zimmerman wrote. 'We think the potential likely path is that insiders may help support the company in order to give it some breathing room to get towards the finish line.' Recommended Reading Vicarious Surgical names Stephen From as next CEO
Yahoo
2 hours ago
- Yahoo
Nike Founder Phil Knight Announces Historic $2 Billion Donation
Nike Founder Phil Knight Announces Historic $2 Billion Donation originally appeared on The Spun. Phil Knight, the co-founder and chairman of Nike, made a record-breaking donation this week that should make plenty of people smile. Knight and his wife, Penny, gifted $2 billion to the Oregon Health & Science University's Knight Cancer Institute. According to Thursday's press release, the plan is to invest in "cancer research, diagnosis, treatment, care, and some day, eradication." The Knight family's $2 billion investment will go down as the largest donation a U.S. educational institution has ever received. "This gift is an unprecedented investment in the millions of lives burdened with cancer, especially patients and families here in Oregon," OHSU President Shereef Elnahal said. "It is also a signal of trust in the superlative work that our clinicians, researchers and teammates at the Knight Cancer Institute do every day. Dr. Druker's vision around a multidisciplinary system of care — focused squarely on making the patient's experience seamless from the moment they receive a diagnosis — will now become reality. And thanks to the extraordinary generosity of Mr. and Mrs. Knight, Oregon will be the place to do it." Phil and Penny have worked with Brian Druker and the Knight Cancer Institute's team in the past, so they clearly felt confident giving them $2 billion. "Penny and Phil Knight have always challenged us to do what no one else is doing," Dr. Druker said. "It can seem impossible to navigate the health care system after being diagnosed with cancer. We're going to change that. We have revolutionized the way we detect and treat cancer. Now we are going to transform the way we care for patients while continuing to develop innovative treatments." Hopefully, this groundbreaking donation from the Knight family will be a game-changer for cancer research around the world. Nike Founder Phil Knight Announces Historic $2 Billion Donation first appeared on The Spun on Aug 14, 2025 This story was originally reported by The Spun on Aug 14, 2025, where it first appeared. Solve the daily Crossword
